Want to see SLDB full AI Analyst Report?
SLDB Stock Chart & Stats
$9.89
-$0.15(-1.88%)
At close: 4:00 PM EDT
$9.89
-$0.15(-1.88%)
Day’s Range― - ―
52-Week Range$3.79 - $11.45
Previous CloseN/A
Volume1.09M
Average Volume (3M)2.23M
Market Cap
$1.06B
Enterprise Value$1.08K
Total Cash (Recent Filing)$377.68M
Total Debt (Recent Filing)$20.16M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Nov 11, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.91
Shares Outstanding107,225,235
10 Day Avg. Volume1,056,120
30 Day Avg. Volume2,232,540
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.74
Price to Sales (P/S)0.00
P/FCF Ratio-3.13
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$19.17Price Target Upside93.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Balance-sheet LeverageModest leverage limits fixed financial obligations and preserves flexibility as Solid advances its pipeline. Although losses remain substantial, the relatively light debt burden reduces balance-sheet pressure compared with a highly indebted clinical-stage biotech.
Expanded Access To Equity FinancingThe expanded shelf gives Solid a defined mechanism to fund research, clinical development and operations when needed. Access to capital markets can support continuity of strategic programs, although the financing route may carry shareholder dilution.
Leadership And Oversight ContinuityContinued board, management and auditor support provides organizational stability during a capital-intensive development period. Consistent oversight can help maintain execution discipline and reporting continuity while the company works toward clinical and regulatory milestones.
Bears Say
No Current Commercial RevenueWith no recent commercial revenue, Solid lacks an operating income base to fund development internally. Financial performance therefore depends on successful clinical and regulatory progress before products or partnerships can generate durable revenue streams.
Widening Losses And Negative Gross ProfitIncreasing losses and negative gross profit indicate that the current cost structure is not supported by operating revenue. Unless development programs create future commercial or partnership income, prolonged losses will continue to weaken returns and consume financial resources.
Heavy And Worsening Cash BurnThe scale and deterioration of cash burn imply continued dependence on external funding to sustain research and clinical activities. This raises financing execution risk and could constrain strategic choices if capital markets become less available or development costs rise.
Solid Biosciences News
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $3.79 and its highest was $11.45 in the past 12 months.
What is Solid Biosciences’s market cap?
Solid Biosciences’s market cap is $1.06B.
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on Aug 06, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.462 by $0.082.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -0.41.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 107,225,235 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.462. Following the earnings report the stock price went down -3.674%.
Which hedge fund is a major shareholder of Solid Biosciences?
Currently, no hedge funds are holding shares in SLDB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solid Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.17 (93.80% Upside)
$19.17 (93.80% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 3.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
36.42%
Trailing 12-Months
Company Description
Solid Biosciences
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
SLDB Stock 12 Month Forecast
Average Price Target
$19.17
▲(93.80% Upside)
Technical Analysis
Ownership Overview
12.09% Insiders
9.98% Mutual Funds
62.60% Other Institutional Investors
2.89% Public Companies and
Individual Investors